Altimmune, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $41,000 | $20,000 | $426,000 | -$68,000 | $4.4M |
| Research and development | $66.4M | $82.2M | $65.8M | $70.5M | $74.5M |
| Operating expenses | $94.5M | $103.2M | $96.4M | $87.7M | $101.3M |
| Operating income | -$94.5M | -$103.2M | -$95.9M | -$87.7M | -$96.9M |
| Interest expense | $1.6M | $9,000 | $35,000 | $8,000 | $5,000 |
| Pretax income | -$88.8M | -$95.1M | -$88.4M | -$84.9M | -$97.1M |
| Income tax expense | -$681,000 | — | — | -$197,000 | — |
| Net income | -$88.1M | -$95.1M | -$88.4M | -$84.7M | -$97.1M |
| Balance Sheet | |||||
| Cash and equivalents | $43.8M | $36.9M | $135.1M | $111.1M | $190.3M |
| Current assets | $278.2M | $137.3M | $209.6M | $192.8M | $204.1M |
| Total assets | $279.9M | $139.3M | $210.6M | $206.9M | $218.9M |
| Current liabilities | $15.0M | $10.5M | $12.1M | $17.1M | $18.3M |
| Total liabilities | $55.0M | $15.8M | $16.5M | $21.6M | $19.7M |
| Total debt | $35.0M | — | — | — | — |
| Stockholders' equity | $224.9M | $123.5M | $194.1M | $185.3M | $199.1M |
| Cash Flow Statement | |||||
| Cash from operations | -$67.5M | -$79.8M | -$75.8M | -$62.6M | -$78.2M |
| Depreciation and amortization | $112,000 | $238,000 | $477,000 | $205,000 | $551,301 |
| Stock-based compensation | $16.1M | $14.4M | $10.6M | $8.1M | $5.5M |
| Capital expenditure | $11,000 | — | $47,000 | $126,000 | $12.1M |
| Free cash flow | -$67.5M | — | -$75.9M | -$62.7M | -$90.4M |
| Impairments | $0 | $0 | $0 | — | $0 |
Shares outstanding 194.5M · Free float 89.5%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.